Related Experiment Video

Updated: Aug 17, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

A patient with carnitine-acylcarnitine translocase deficiency with a mild phenotype

A A Morris1, S E Olpin, M Brivet

  • 1Institute of Child Health, London, United Kingdom.

The Journal of Pediatrics
|April 17, 1998
PubMed

Insights

Carnitine-acylcarnitine translocase deficiency typically causes severe early-childhood complications. However, one patient with this rare beta-oxidation defect experienced a benign clinical course due to higher residual enzyme activity.

Area of Science:

  • Biochemistry
  • Metabolic disorders
  • Genetics

Background:

  • Carnitine-acylcarnitine translocase deficiency is a rare inherited metabolic disorder.
  • It is a defect in the beta-oxidation pathway, crucial for energy production.
  • The condition often leads to severe health issues like cardiomyopathy and early death.

Observation:

  • A case study of a 3-year-old patient with carnitine-acylcarnitine translocase deficiency is presented.
  • This patient exhibited an unusually mild clinical presentation.
  • No serious complications were observed in the patient despite the diagnosis.

Findings:

  • The patient displayed higher residual carnitine-acylcarnitine translocase enzyme activity in fibroblasts compared to previously reported cases.
  • This elevated enzyme activity is hypothesized to correlate with the benign clinical outcome.
  • Suggests a potential link between enzyme function level and disease severity.

Implications:

  • Highlights the potential for milder presentations of carnitine-acylcarnitine translocase deficiency.
  • Indicates that residual enzyme activity may be a key determinant of clinical course.
  • Suggests further research into genotype-phenotype correlations and therapeutic strategies for beta-oxidation defects.

More Related Videos

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine09:54

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Published on: November 4, 2018

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome06:48

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome

Published on: March 23, 2022

Related Concept Videos

Pedigree Analysis01:35

Pedigree Analysis

Overview
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...